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Abstract
Background: Neuroendocrine prostate cancer (NEPC) is a highly aggressive subtype of prostate cancer (PCa) for
which the median survival remains less than a year. Current treatments are only palliative in nature, and the lack of
suitable pre-clinical models has hampered previous efforts to develop novel therapeutic strategies. Addressing this
need, we have recently established the first in vivo model of complete neuroendocrine transdifferentiation using
patient-derived xenografts. Few genetic differences were observed between parental PCa and relapsed NEPC, suggesting
that NEPC likely results from alterations that are epigenetic in nature. Thus, we sought to identify targetable epigenetic
regulators whose expression was elevated in NEPC using genome-wide profiling of patient-derived xenografts
and clinical samples.
Results: Our data indicate that multiple members of the polycomb group (PcG) family of transcriptional repressors
were selectively upregulated in NEPC. Notably, CBX2 and EZH2 were consistently the most highly overexpressed
epigenetic regulators across multiple datasets from clinical and xenograft tumor tissues. Given the striking upregulation
of PcG genes and other transcriptional repressors, we derived a 185-gene list termed ‘neuroendocrine-associated
repression signature’ (NEARS) by overlapping transcripts downregulated across multiple in vivo NEPC models. In line
with the striking upregulation of PcG family members, NEARS was preferentially enriched with PcG target genes,
suggesting a driving role for PcG silencing in NEPC. Importantly, NEARS was significantly associated with high-grade
tumors, metastatic progression, and poor outcome in multiple clinical datasets, consistent with extensive literature
linking PcG genes and aggressive disease progression.
Conclusions: We have explored the epigenetic landscape of NEPC and provided evidence of increased PcG-mediated
silencing associated with aberrant transcriptional regulation of key differentiation genes. Our results position CBX2 and
EZH2 as potential therapeutic targets in NEPC, providing opportunities to explore novel strategies aimed at reversing
epigenetic alterations driving this lethal disease.
Keywords: Neuroendocrine prostate cancer, Patient-derived xenografts, Epigenetics, Polycomb, CBX2, EZH2,
Therapeutics, Prognosis
Background
With a median survival of less than a year, neuroendocrine
prostate cancer (NEPC) represents the most aggressive
prostate malignancy and only a small fraction of NEPC
patients benefit from current treatments [1]. While
NEPC may arise de novo, most cases result from the
transdifferentiation of a typical prostate adenocarcinoma
(PCa) into NEPC following androgen-deprivation therapy
(ADT) [2,3]. Histologically, NEPC is characterized by the
presence of small round cells with a prominent nucleus
and scant cytoplasm. Typically arranged in a monomorphic
pattern, NEPC cells stain positive for neuroendocrine
markers such as chromogranin A (CHGA) and synapto-
physin (SYP) but negative for PCa markers like androgen
receptor (AR) and prostate-specific antigen (PSA) [4].
Since NEPC cells lack AR expression, they probably arise
by positive selection following AR suppression, thus pro-
viding an adaptive mechanism to achieve castration
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resistance [5]. Accordingly, due to the recent FDA approval
of potent AR-targeting drugs in patients receiving ADT,
NEPC incidence is expected to dramatically rise in the near
future, creating an urgent need for improved therapeutics
[5]. Emerging evidence suggests that epigenetic alterations
may be involved in neuroendocrine transdifferentiation
(NETD) [6,7], providing unexplored opportunities to iden-
tify novel drug targets for this invariably lethal disease.
Epigenetics is a broad term that encompasses all mi-
totically and meiotically heritable changes in chromatin
structure and gene expression that do not result from
alterations in DNA sequence [8]. Epigenetic regulation
is conferred by covalent modifications on DNA and
histones, which define the transcriptional activity of
surrounding genomic regions [9]. Historically, the first
epigenetic modification discovered was DNA methyla-
tion at CpG dinucleotides, a mark typically correlating
with transcriptional silencing [10,11]. On histones, nu-
merous chemical modifications can be enzymatically
added and removed from N-terminal tails by a large
network of epigenetic regulators (EpRs), giving rise to a
highly complex ‘histone code’ [12]. Examples of post-
translational modifications include methylation, acetyl-
ation, ubiquitination, phosphorylation, and many others
that are starting to gain recognition [13]. The transcrip-
tional effect conferred by these modifications depends
on the particular chemical mark as well as the residue
on which it is deposited [14]. Three main types of EpRs
dynamically control chromatin: 1) writers, which catalyze
the addition of covalent modifications; 2) erasers, which
remove these marks; and 3) readers, which directly bind
epigenetic modifications [15]. Readers can simultaneously
interact with chromatin-remodeling factors, thereby re-
shaping the epigenome in a reversible fashion [15]. Im-
portantly, almost all EpRs lie downstream of signal
transduction pathways, allowing for dynamic chromatin
modulation in response to external cues [16]. Accordingly,
epigenetic regulation plays a key role in fundamental pro-
cesses that involve changes in phenotypic identity such as
development and cancer [17,18]. Since epigenetic modifi-
cations are reversible, EpRs can be pharmacologically tar-
geted by small molecule inhibitors, and a rapidly growing
number of ‘epi-drugs’ are receiving FDA approval [19].
Given the growing interest in identifying clinically rele-
vant epigenetic alterations, considerable attention has
been given to the polycomb group (PcG) gene family in
the context of human cancer [20]. PcG proteins represent
important epigenetic silencers that have been strongly
linked to cellular de-differentiation and malignant pro-
gression [21]. Assembling into two main polycomb repres-
sive complexes (PRC1 and PRC2), these proteins regulate
hundreds of genes involved in major cell fate decisions
[22]. In the classical PcG silencing model, PRC2 trimethy-
lates histone H3 at lysine 27 (H3K27me3), through its
catalytic subunit EZH2 [23]. This repressive chromatin
mark can be directly recognized by the N-terminal chro-
modomain of chromobox proteins (CBX2,4,6,7,8) [24],
which then recruit PRC1 members to chromatin via a C-
terminal domain [25]. At genomic sites, PRC1 can then
monoubiquitylate histone H2A (H2AK119ub) through its
catalytic components RING1A or RING1B, which further
represses PcG target loci [26]. To date, dysregulation of
PcG-mediated silencing has been observed in many ag-
gressive tumor types but has not been studied in NEPC.
Interestingly, PcG genes are required for neurogenesis and
neural stem cell survival [27-29], implying that they may
regulate differentiation into neuronal lineages. In line with
this idea, we and others have recently shown that EZH2
mRNA levels are upregulated in NEPC [7], suggesting that
alterations in PcG-mediated repression may be involved in
NEPC pathogenesis.
Given the lack of xenograft and cell line models to study
NEPC, we established the first in vivo model of ADT-
induced NEPC using patient-derived xenografts implanted
in the mouse subrenal capsule at the Living Tumor
Laboratory [6]. Our initial analysis revealed that the ori-
ginal PCa (LTL331) and the relapsed NEPC (LTL331R)
tumor lines share a remarkably similar genetic profile, sug-
gesting that epigenetic alterations were likely to drive
NEPC [6]. We therefore conducted comparative gene ex-
pression analysis between LTL331R and LTL331, as well
as in a clinical NEPC cohort, to identify EpRs that were
differentially expressed in NEPC. Our data demonstrate
that multiple PcG family members are overexpressed in
NEPC, notably CBX2 and EZH2. Consistent with these
results, we derived a neuroendocrine-associated repression
signature (NEARS) that predicted aggressive disease
progression and was enriched in PcG targets. Overall,
our results support a clinically relevant function for PcG-
mediated silencing, revealing novel targets for development
of epigenetic therapies in the context of lethal NEPC.
Results
Expression profiling of epigenetic regulators in NEPC
To uncover potential therapeutic targets in NEPC, we
set out to identify upregulated genes in the LTL331R/
LTL331 xenograft model, as well as in a clinical NEPC
dataset containing gene expression profiling of PCa and
NEPC patient tumors [7]. We initially established a list
of EpRs using criteria that would maximize the transla-
tional application of identified targets. For these reasons,
we restricted our list to the epigenetic writers, erasers,
and readers regulating histone acetylation and methyla-
tion, as well as DNA methylation [30]. Furthermore, the
selected genes were also functionally classified into those
associated with transcriptional activation or repression,
and EpRs for which the transcriptional role remains un-
clear. Using a panel of recent comprehensive reviews, we
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derived a list of 147 EpRs that we subsequently analyzed
in our NEPC expression datasets (Table 1, Additional file 1:
Table S1).
To investigate the epigenetic landscape of NEPC, we
assessed the differential expression of our EpR list in the
clinical NEPC cohort and the LTL331R/LTL331 micro-
array dataset [6,7]. First, we determined if there was
preferential upregulation of readers, writers, or erasers
and observed no significant difference (Figure 1A, non-
significant, Kruskal-Wallis test). The same analysis was
conducted investigating factors affecting different chroma-
tin modifications (histone acetylation and methylation,
DNA methylation) and demonstrated that no expression
differences could be detected between EpRs associated
with these chemical marks (Figure 1B, non-significant,
Kruskal-Wallis test). However, we found that the mRNA
levels of transcriptional repressors were significantly
higher than that of activators in NEPC, which may result
in a more repressed chromatin state that potentially regu-
lates neuroendocrine differentiation (Figure 1C, P < 0.05,
Kruskal-Wallis test). Next, starting from our 147 EpR list
described earlier (Table 1), we selected 22 genes that were
upregulated in both the LTL331R/LTL331 model and the
clinical cohort (expression shown in Additional file 1:
Table S1, cutoff fold change (FC) in both >1.5). Expression
of these 22 EpRs was significantly correlated between
the clinical cohort and the LTL331R model (Figure 1D,
R2 = 0.48, P < 0.001, Spearman test), indicating that
gene expression in our xenograft model accurately
reproduced the transcriptional profiles observed in the
clinical setting. As expected, most of the selected EpRs
were preferentially involved in transcriptional repression,
accounting for 68% of all selected EpRs (Figure 1E). To as-
sess the clinical relevance of these genes, we investigated
whether their elevated expression was associated with spe-
cific parameters of prostate cancer progression in the
Oncomine database [31]. Using stringent inclusion criteria
(P < 0.005, odds/ratio > 5, top 10% overexpressed), we
identified five independent Oncomine studies in which
this gene list was significantly upregulated in disseminated
prostate tumors (Additional file 2: Table S2). Since these
datasets were mostly derived from localized PCa tissue,
this indicates that elevated expression of those 22 EpRs
in primary PCa may predispose tumors for an aggres-
sive and metastatic progression, consistent with NEPC
pathogenesis.
To further characterize these epigenetic alterations, we
focused on individual genes that were aberrantly regu-
lated in both the clinical NEPC cohort and in LTL331R.
An important finding was that the PcG H3K27me3
reader CBX2 was the most highly overexpressed tran-
script in both datasets (Figure 1E, FC 331R/331 = 8.2, FC
NEPC/PCa = 10.2). Interestingly, the H3K27me3 writer
EZH2 was the second most highly upregulated transcript
(Figure 1E, FC 331R/331 = 3.4, FC NEPC/PCa = 9.2), im-
plying that H3K27me3 and its downstream epigenetic
effects may be potentiated in the molecular context of
NEPC. Of note, the selected gene list also included two
other PRC1-containing CBX proteins, CBX6 and CBX8
(Figure 1E), further supporting a role for dysregulated
PcG-mediated silencing during neuroendocrine transdiffer-
entiation. In addition to the increase in PcG genes them-
selves, we also observed that 73% of non-PcG repressors in
our list of upregulated EpRs have been reported to directly
interact with at least one PcG member (Additional file 3:
Table S3). These PcG-interacting proteins were mainly
involved in DNA methylation (DNMT1, DNMT3A,
DNMT3B, MBD1) and histone methylation (SUV39H1,
DOT1L, CHD5, CBX3), suggesting that the upregulation
of other EpRs may contribute to the effect of altered PcG-
mediated silencing in NEPC [32,33].
PcG gene expression in LTL patient-derived xenografts
Since the most aberrantly expressed transcripts were
members of the PcG family (Figure 2A, P < 0.001, Mann-
Whitney U test), we compared the expression of 36
known PcG genes (Additional file 4: Table S4) in ten PCa
and three NEPC xenografts from the Living Tumor La-
boratory using microarray data we have previously pub-
lished [6] (models and their properties listed in Additional
file 5: Table S5). To ensure that our xenograft models
retained typical features of their respective subtype, we
assessed expression of molecular markers specific to PCa
(AR, PSA) and NEPC (SYP, CHGA) in the investigated
Living Tumor Lab (LTL) tumor lines. As expected, expres-
sion of these markers segregated perfectly between the
two malignancies. AR and PSA were selectively upregu-
lated 489- and 124-fold in PCa over NEPC, respectively
(Figure 2B, P < 0.0001, Mann-Whitney U test). In contrast,
SYP and CHGA respectively exhibited a 21- and 854-fold
enrichment in neuroendocrine tumor lines compared
to PCa models (Figure 2B, P < 0.0001, Mann-Whitney
U test). Having confirmed that our patient-derived xe-
nografts were transcriptionally representative of each
Table 1 Distribution of 147 investigated epigenetic
regulators across different epigenetic modifications,
activities, and transcriptional effects
Criteria Epigenetic regulator distribution
Epigenetic
modification
DNA
methylation
Histone
acetylation
Histone
methylation
13 (9%) 65 (44%) 69 (47%)
Writer Eraser Reader
53 (36%) 40 (27%) 54 (37%)
Activation Repression Unclear
72 (49%) 66 (45%) 9 (6%)
Total 147 genes
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subtype, we assessed the expression of PcG genes in the
same models. Of the 36 PcG genes that were queried
(Additional file 4: Table S4), ten were significantly upregu-
lated (Figure 2C, P < 0.05, Mann-Whitney U test). As ob-
served in the LTL331R/LTL331 model and in the clinical
NEPC dataset, CBX2 and EZH2 were again the two most
highly overexpressed genes with fold changes of 5.8 and
4.7, respectively (Figure 2C, P < 0.0001, Mann-Whitney U
test). In addition, overabundance of CBX6 and CBX8
transcripts was also observed in neuroendocrine tumor
lines (Figure 2C, P < 0.05, Mann-Whitney U test), consist-
ent with our previous findings. Notably, all core PRC2
members (EED, EZH1, EZH2, SUZ12) were significantly
upregulated in NEPC (Figure 2C, P < 0.05, Mann-Whitney
U test). In addition, we found a significant correlation be-
tween expression of PcG genes in the LTL331R/LTL331
Figure 1 Differential expression of epigenetic regulators in NEPC. Average fold change of individual EpRs grouped by distinct (A) epigenetic
modifications, (B) epigenetic activities, and (C) transcriptional effects in clinical NEPC/PCa and the 331R/331 model. (D) Expression correlation of
22 EpRs upregulated by more than 1.5-fold in clinical NEPC/PCa and the 331R/331 model. (E) Expression levels of individual upregulated EpRs in
clinical NEPC/PCa and the 331R/331 model.
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model and in the clinical cohort (Figure 2D, R2 = 0.68,
P < 0.0001, Spearman test), validating reproducible PcG
upregulation across all investigated datasets.
Since we found that CBX2 and EZH2 were consist-
ently the most upregulated EpRs in our NEPC models,
we further investigated the molecular profiles of these
two PcG members. Using immunohistochemistry (IHC),
we analyzed CBX2 and EZH2 protein expression in the
LTL331R/LTL331 model. We first used antibodies to
PSA and SYP to confirm that LTL331 and LTL331R re-
tain the histological features of PCa and NEPC, respect-
ively (Figure 3). As expected, PSA expression was very
strong in LTL331 while LTL331R displayed undetectable
levels. In contrast, SYP immunoreactivity was strictly
restricted to LTL331R, in line with the expected histo-
logical profiles of each tumor line. Having validated our
positive and negative controls for each subtype, we ana-
lyzed CBX2 and EZH2 protein levels in both tumor lines
(Figure 3). In accordance with high mRNA levels, CBX2
exhibited strong immunoreactivity in LTL331R while
displaying only weak positivity in LTL331. Similarly,
EZH2 protein expression was extremely high in basically
all LTL331R cells, although most LTL331 cells also dis-
played moderate to strong EZH2 immunostaining. Taken
together, these data demonstrate that CBX2 and EZH2
are highly overexpressed at both the mRNA and protein
levels in NEPC.
Focusing on EZH2 and CBX2, we investigated whether
elevated expression of these two PcG members also oc-
curred in small cell lung cancer (SCLC), since it represents
a neuroendocrine malignancy that closely resembles
NEPC histologically and molecularly [34,35]. The relative
mRNA levels of CBX2 and EZH2 were therefore assessed
in SCLC and compared to two epithelial lung cancer
subtypes, lung adenocarcinoma (AC) and squamous
cell carcinoma (SqCC) [36]. We report that both CBX2
and EZH2 were significantly overexpressed in SCLC
compared to epithelial counterparts [37] (Figure 4A,B,
P < 0.0001 for both genes, Kruskall-Wallis test). In addition,
CBX2 and EZH2 expression was strongly correlated in a
clinical SCLC cohort (R2 = 0.59, Figure 4C), suggesting that
these two PcG proteins likely act in concert. Thus, the
selective involvement of CBX2 and EZH2 in aggressive
neuroendocrine tumors may not be restricted to NEPC.
Another similarity between NEPC and SCLC is that
both malignancies were reported to have frequent RB1
inactivation, which contributes to their high proliferative
rate [38,39]. Thus, we investigated the RB1 status in our
patient-derived xenograft models. As expected, RB1 ex-
pression was relatively high in almost all PCa xenografts
Figure 2 Coordinated increase in PcG gene expression. (A) Average fold change of non-PcG and PcG genes from unselected 147 EpR list and
selected 22 EpR list. (B) Expression of typical prostate neuroendocrine (SYP, CHGA) and adenocarcinoma (AR, PSA) markers in selected xenograft models.
(C) Coordinated upregulation of core PRC1 and PRC2 members led by CBX2 and EZH2 in selected xenograft models. (D) Significant correlation between
PcG gene expression in all LTL xenograft models and 331R/331 model.
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while the expression of CBX2 and EZH2 was consider-
ably lower (Additional file 6: Figure S1). Conversely, the
expression of RB1 was undetectable in the NEPC tumor
lines LTL352 and LTL370 while LTL331R exhibited a
modest increase (Additional file 6: Figure S1). Genomic
characterization of these models revealed that both
LTL352 and LTL had homozygous RB1 deletion while
LTL331R had a monoallelic loss and a hemyzygous mu-
tation in RB1 (Wyatt et al. unpublished). Taken together,
these data suggest that aberrant PcG-mediated silencing
may cooperate with RB1 inactivation to sustain the high
proliferative rate of NEPC.
Polycomb silencing and neuroendocrine-associated
repression signature
Since our initial analysis revealed that epigenetic repres-
sors, in particular the PcG genes, were significantly up-
regulated in NEPC, we investigated whether we could
infer molecular and clinical information from the genes
downregulated in NEPC. We therefore derived a gene
Figure 3 CBX2 and EZH2 protein expression in NEPC. Immunohistochemical analysis of (A) PSA, (B) SYP, (C) EZH2, and (D) CBX2 in the 331R/331
xenograft model (×20).
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signature by combining the list of genes whose expres-
sion decreased by at least twofold (50%) in three inde-
pendent scenarios: 1) LTL331R vs LTL331, 2) clinical
NEPC vs PCa, and 3) LTL331 vs all other LTL PCa. The
latter was investigated under the hypothesis that LTL331
may be ‘predisposed’ to transdifferentiate compared to
other PCa tumor lines. Thus, using this 50% threshold,
we established a list of 185 genes silenced in NEPC,
which we termed the NEARS (Figure 5, Additional file
7: Table S6). We first used the Oncomine database [31]
to identify molecular ‘concepts’ (that is, sets of genes de-
rived from previously published experiments) that were
significantly associated with NEARS. In line with the
striking upregulation of PcG genes, this analysis revealed
that, of the thousands of concepts present on Oncomine,
6 of the top 12 concepts were directly linked to PcG-
mediated silencing (Table 2, odds ratios = 3.7 to 5.0, P =
3.4 × 10−9 to 1.2 × 10−15). These six concepts specifically
overlapped with target genes of known PcG members
CBX8, SUZ12, and EED, as well as H3K27me3. Of note,
these concepts were derived from experiments con-
ducted either in embryonic stem cells or in embryonic
fibroblasts, consistent with the role of PcG complexes in
undifferentiated cells [22]. As an unexpected indicator of
quality control, we also found that two concepts strongly
linked to NEARS included ‘downregulated genes in
prostate cancer after androgen ablation therapy’ and ‘up-
regulated genes in prostate cancer cells in response to
synthetic androgen R1881’, two concepts sharing 19
genes (odds ratios = 20.5, P < 3.662 × 10−18). These con-
cepts describe genes that are likely AR-regulated [40],
and therefore their downregulation is expected in NEPC
cells given their lack of AR expression. Taken together,
our results demonstrate that NEARS is enriched in PcG
targets and preferentially contains genes regulated by
AR transactivation.
PcG gain of function usually correlates with poor pa-
tient prognosis, and our results suggest that the NEARS
preferentially contains many PcG targets. Thus, we
sought to determine whether NEARS was also associated
with clinical parameters indicative of aggressive PCa
progression. Using the Oncomine database, we analyzed
the differential expression of NEARS in tumors of differ-
ent metastatic potential, grade, and prognosis. Strikingly,
significant downregulation of NEARS was observed in
metastatic compared to primary prostate malignancies
in six independent datasets (Table 3, odds ratios = 2.4 to
6.0, P = 4.5 × 10−4 to 2.0 × 10−26). Likewise, NEARS un-
derexpression was also recorded in eight clinical PCa
datasets (Table 3, odds ratios = 2.2 to 7.6, P = 3.4 × 10−4
to 1.9 × 10−8). Finally, six additional datasets displayed
reduced NEARS expression in patients with poor clinical
outcome (Table 3, odds ratios = 2.4 to 15.2, P = 2.0 × 10−3
to 1.0 × 10−11), further supporting the idea that dowre-
gulation of PcG target genes correlates with aggressive
disease progression. Overall, our results demonstrating
that NEARS contains many conserved PcG genomic
targets and that multiple PcG genes are highly upregulated
Figure 4 Regulation of PcG proteins CBX2 and EZH2 in lung
cancer subtypes. (A) CBX2 and (B) EZH2 mRNA levels in
non-neuroendocrine (AC and SqCC) and neuroendocrine (SCLC)
lung malignancies. (C) Correlation between CBX2 and EZH2
mRNA levels in SCLC (data from CLGCP).
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in NEPC strongly suggest that altered PcG-mediated silen-
cing plays a key role in establishing and maintaining the
NEPC phenotype.
Discussion
NEPC is an incurable malignancy which is expected to
become more prevalent given the widespread use of po-
tent AR-targeting drugs, which positively select for AR-
negative NEPC cells [41]. However, the lack of suitable
pre-clinical NEPC models has limited investigations into
the molecular underpinnings of NEPC, therefore ham-
pering therapeutic development of novel agents to treat
this deadly disease. To circumvent this issue, we estab-
lished a high fidelity, patient-derived xenograft model
retaining classical NEPC features observed in the clinic
[6] that allows us to investigate the molecular mechanisms
involved in NEPC transdifferentiation. Using this model,
we identified many PcG genes that are dysregulated in
NEPC, a finding that was also observed in a clinical cohort
and in additional patient-derived NEPC xenografts from
the Living Tumor Laboratory. Moreover, we derived a
NEARS that was predictive of PcG gain of function and
aggressive disease progression. Based on these results, we
propose that aberrant PcG-mediated silencing contributes
to NEPC pathogenesis and that disrupting PcG activity
may emerge as a valuable therapeutic strategy in NEPC.
Within the epigenetic landscape of NEPC, there was a
global upregulation of repressive EpRs, and more than
70% of them were reported to directly interact with PcG
complexes. Notably, all three genes encoding DNMTs
were overexpressed in NEPC, suggesting that aberrant
DNA methylation may synergize with alterations in
Figure 5 Establishment and Oncomine analysis of a 185-gene ‘neuroendocrine-associated repression signature’ (NEARS) derived from
datasets originating from NEPC models.
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PcG-mediated repression. In line with those results, in-
creasing evidence supports the idea that PcG activity
dictates DNMT recruitment to chromatin at target loci,
implying a central role for PcG complexes in DNA
methylation and its resulting epigenetic effects [42,43].
Aberrant DNA methylation has previously been reported
in PCa, and the question of how DNA methylation
patterns vary between PCa and NEPC remains unanswered
[44]. Since cell fate transitions involve differential DNA
methylation at enhancer regions [45], an attractive hy-
pothesis is that PcG complexes and DNMTs synergize
to regulate key enhancers relevant to neuroendocrine
transdifferentiation. Consequently, future experiments
should explore the distribution of DNA methylation in
Table 3 Correlations between downregulation of NEARS and poor prognostic factors in clinical prostate tumors
Clinical parameters associated with NEARS
Analysis Concept Dataset Odds ratio P value Percentile Samples
1° vs Met Metastasis Lapointe Prostate 2.4 1.3E-04 Top 10% 71
Metastasis LaTulippe Prostate 2.4 4.5E-04 Top 10% 32
Metastasis Yu Prostate 3.5 2.0E-07 Top 10% 88
Metastasis Grasso Prostate 3.8 5.6E-13 Top 10% 94
Metastasis Vanaja Prostate 4.6 8.4E-18 Top 10% 32
Metastasis Taylor Prostate 3 6.0 2.0E-26 Top 10% 150
Grade Advanced Gleason Score Wallace Prostate 2.2 3.4E-04 Top 10% 65
Advanced Gleason Score Vanaja Prostate 2.4 6.6E-06 Top 10% 27
Advanced Gleason Score Lapointe Prostate 3.4 1.8E-05 Top 5% 61
Advanced Gleason Score Tomlins Prostate 3.6 1.9E-08 Top 10% 30
Advanced Gleason Score Taylor Prostate 3 3.6 4.4E-08 Top 5% 130
Advanced Gleason Score Yu Prostate 4.4 4.1E-07 Top 5% 61
Advanced Gleason Score Setlur Prostate 7.6 2.8E-04 Top 1% 353
High Grade Bittner Prostate 2.5 3.3E-04 Top 5% 46
Outcome Dead at 3 years Setlur Prostate 2.4 2.0E-03 Top 10% 358
Recurrence at 5 years Taylor Prostate 3 3.1 1.3E-09 Top 10% 61
Recurrence at 3 years Taylor Prostate 3 3.5 1.0E-11 Top 10% 107
Recurrence at 5 years Nakagwa Prostate 10.1 1.0E-03 Top 10% 592
Dead at 5 years Setlur Prostate 10.7 2.9E-06 Top 1% 363
Recurrence at 3 years Nakagwa Prostate 15.2 7.9E-04 Top 5% 594
Table 2 List of top 12 literature-derived concepts most significantly associated with NEARS
NEARS literature-defined Oncomine concept analysis
Rank Concept PcG-related P value Q value Odds ratio
1 CBX8 target genes in human embryonic fibroblasts X 1.2E-15 9.6E-12 5.0
2 Upregulated genes in neutrophils compared to other blood cells 7.4E-13 3.8E-10 6.5
3 Downregulated in human embryonic stem cells vs differentiated counterparts 1.3E-13 5.8E-10 6.9
4 Downregulated genes in prostate cancer after androgen ablation therapy 4.9E-12 1.5E-8 20.5
5 SUZ12 target genes in human embryonic stem cells X 5.2E-12 1.5E-8 6.4
6 Trimethylated H3K27 target genes in human embryonic stem cells X 2.5E-11 4.8E-8 5.9
7 DrugBank targets - FDA approved 5.6E-11 1.0E-8 12.3
8 Upregulated genes in weakly invasive colon cancer cells 5.6E-11 1.0E-7 12.3
9 Polycomb group target genes in human embryonic stem cells X 7.0E-10 8.4E-7 7.1
10 Upregulated genes in prostate cancer cells in response to synthetic androgen R1881 9.1E-10 9.5E-7 11.0
11 EED target genes in human embryonic fibroblasts X 1.8E-9 1.8E-6 5.4
12 Trimethylated H3K27 target genes in human embryonic fibroblasts X 3.4E-9 2.8E-6 3.7
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the context of genome-wide PRC1 and PRC2 chroma-
tin binding in NEPC cells.
In line with the upregulation of PcG genes observed
in NEPC, we derived a list of genes recurrently silenced
in multiple NEPC models (NEARS) that was strongly
associated with PcG-mediated repression. Moreover, si-
lencing of NEARS in localized PCa tissue predicts an
aggressive clinical course, consistent with the notion
that certain PCas may be predisposed to acquire
neuroendocrine-like features in a PcG-dependent man-
ner. Interestingly, NEARS contained many PcG target
genes in embryonic stem cells, implying that PcG activ-
ity in NEPC may suppress epithelial differentiation
through silencing of genes specifying specialization into
prostatic tissues, particularly since NEARS included
some AR-regulated genes. In line with this idea, epigenetic
reprogramming of a similar nature has been repeatedly
observed in many aggressive tumor types featuring aber-
rant PcG-mediated repression [21]. In addition, neurogen-
esis is PcG-dependent [29,46], thus it seems likely that the
activation of neuroendocrine-specific transcriptional
programs may also be facilitated by increased PcG ac-
tivity. Supporting this idea, we observed preferential
overexpression of PcG genes CBX2 and EZH2 in SCLC,
which represents a lung cancer subtype with neuroendo-
crine differentiation. Taken together, these results suggest
that gene expression profiles regulated by PcG genes dur-
ing normal embryogenesis are re-established in NEPC and
possibly other neuroendocrine malignancies.
Despite playing imperative roles during embryonic de-
velopment [47], CBX2 has been overlooked for many
years in the cancer literature. Genetic inactivation of
CBX2 (M33 in mice) causes lethality in 50% of subjects
and the remaining progeny exhibit gonadal, adrenal, and
splenic defects, reflecting a critical function for CBX2 in
cellular differentiation [47,48]. In this paper, we report
that CBX2 was consistently the most upregulated EpR in
NEPC compared to PCa in our analyzed datasets. These
findings support our recent discovery that CBX2 confers
a genomic and transcriptomic profile consistent with
that of an oncogene [49]. We have shown that high
CBX2 expression correlates with poor patient outcome
and more aggressive tumor phenotypes [49], in line with
the clinical features of NEPC.
From a molecular standpoint, it is important to note
that CBX2 upregulation observed in NEPC occurs in the
context of overexpressed EZH2 and other PRC2 mem-
bers, which likely alters the genomic distribution of the
H3K27me3 mark. This has considerable mechanistic im-
plications since CBX2 can directly bind H3K27me3 and
recruit PRC1 to H3K27me3 sites, which solidifies tran-
scriptional repression at target loci [24]. Thus, CBX2
overexpression might represent an alteration necessary
to mediate the downstream epigenetic effect of PRC2
gain of function. Biochemical evidence supports this hy-
pothesis since, although PRC1 composition varies in a
context-dependent manner, PRC1 complexes found at
H3K27me3 sites are preferentially enriched in CBX2 and
not other CBX proteins [33]. While the relative contribu-
tion of CBX2 compared to other CBX members remains
under investigation, the strong upregulation of CBX2 in
NEPC, in addition to its critical role in cellular differenti-
ation, suggest that CBX2 is functionally involved in the
progression of NEPC.
Finally, we believe that the reported aberrations in
PcG-mediated silencing have clear therapeutic implica-
tions, particularly given the emerging improvements in
targeting the cancer epigenome [50,51]. In particular, we
believe the interaction between CBX2 and H3K27me3
bridges the function of PRC2 and PRC1, thus represent-
ing a critical junction in this altered epigenetic pathway
[52]. A few strategies can be put forward to therapeutic-
ally target this axis in the context of NEPC. First, small
molecule inhibitors interfering with the methyltransfer-
ase activity of EZH2 have already been developed and
warrant further investigation in NEPC [53]. Second, an-
tagonists of the CBX2 chromodomain represent another
promising path, as they would disrupt the binding be-
tween CBX2 and H3K27me3. At present, there are no
small molecules directly targeting CBX2, although the
development of CBX7 antagonists hints that a similar
strategy could also be employed for CBX2 [54,55]. Third,
antisense oligonucleotides (ASOs) may be used to re-
duce the expression of key PcG genes such as CBX2 and
EZH2. An exponentially increasing number of ASOs
have entered clinical testing, highlighting the potential
of ASOs as therapeutic agents [56]. Taken together, our
results highlight relevant alterations in Polycomb-
mediated silencing that may be clinically targetable in le-
thal NEPC, thereby adding to the growing landscape of
cancer epigenetics.
Conclusions
Given the sparsity of adequate pre-clinical NEPC
models, we investigated the epigenetic underpinnings of
NEPC using innovative patient-derived xenograft models
available at the Living Tumor Laboratory. Data obtained
using this model was further validated in a clinical
NEPC cohort. Using an integrative approach, we identified
a striking upregulation of many key PcG genes, notably
CBX2 and EZH2. In addition, we reported a clinically rele-
vant dysregulation of PcG target genes in multiple NEPC
models, consistent with a driving role for PcG complexes.
Thus, our study reveals novel insights into NEPC patho-
genesis and provides the rationale to establish therapeutic
strategies aimed at disrupting altered PcG-mediated
silencing.
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Methods
Clinical expression datasets
Originating from the work of Beltran et al. the clinical
NEPC cohort contained 7 NEPC tumors and 30 PCas
which contained less than 10% stroma, as confirmed by
a certified pathologist [7]. Prognostic analysis of NEARS,
as well as the selected list of EpRs, was conducted using
PCa datasets available from the Oncomine resource
(www.oncomine.com) [31], which encompassed more
than 3,800 patients. Clinical parameters assessed for
differential gene expression included grade, metastasis,
outcome, and stage. Analysis of literature-derived con-
cepts correlated with NEARS was also done through
the Oncomine resource, and the final list was unbiasedly
determined using the lowest P values of associated con-
cepts. Expression profiles of lung malignancies were gen-
erated by The Clinical Lung Cancer Genome Project
(CLCGP) and Network Genomic Medicine (NGM) [37]
(http://www.uni-koeln.de/med-fak/clcgp/).
Gene lists
We established a list of targetable EpRs based on the
following inclusion criteria: 1) being involved either in
DNA methylation, histone acetylation, or histone methyla-
tion and 2) function as a writer, eraser, or reader of the
epigenetic code. EpRs regulating DNA methylation were
also subdivided into the same functional categories as
those established for histone modifications (that is, writer =
DNA methyltransferase (DNMT), eraser = ten eleven trans-
location (TET), reader =methyl CpG-binding domain
(MBD)). Analysis of relevant literature [57-65] was con-
ducted to identify such candidates, which were subse-
quently assessed in our NEPC datasets. In a similar way, a
list of PcG genes was also derived from the literature using
recent review papers written by authorities in the field
[52,66,67]. We also derived a list of repressors that directly
interact with PcG proteins based on literature findings
(Additional file 3: Table S3). Finally, NEARS was established
by combining the 185 genes downregulated in all three of
the following datasets: 1) LTL331R/LTL331, 2) Clinical
NEPC/PCa, and 3) LTL331/all LTL PCa [6].
Immunohistochemistry
Establishment of paraffin-embedded tissue sections and
immunostaining were conducted as previously described
[6,68]. Detection was done using primary antibodies spe-
cific to PSA (rabbit polyclonal, Dako, Glostrup, Denmark),
SYP (mouse monoclonal, Dako), CBX2 (rabbit polyclonal,
Pierce, Rockford, USA), and EZH2 (rabbit monoclonal,
Cell Signaling, Danvers, USA), as well as a goat anti-rabbit
secondary antibody (Vector Laboratory, Peterborough,
UK).
Patient-derived xenografts
As previously described [6], the Living Tumor Lab (www.
livingtumorlab.com) has established a bank of high-fidelity
patient-derived xenografts. Tumor tissues were obtained
from patients through a protocol approved by the Clinical
Research Ethics Board of the University of British
Columbia (UBC) and the BC Cancer Agency (BCCA). All
patients signed a consent form approved by the Ethics
Board (UBC Ethics Board #: H09-01628 and H04-60131;
VCHRI #: V09-0320 and V07-0058). In this study, we used
microarray data derived from ten PCa and three NEPC
tumor lines, all of which retain the classical histological
features of their respective subtype. The microarray gene
expression data for these tumor lines have been previously
deposited in the NCBI Gene Expression Omnibus (GEO)
and are freely available under the accession number
GSE41193.
Statistical analysis
All statistical analyses were carried out with the Graphpad
Prism software (version 6.0) using a statistical threshold of
P ≤ 0.05 unless otherwise stated.
Additional files
Additional file 1: Table S1. List of 147 targetable EpRs. List of 147
targetable EpRs and their associated fold changes in the clinical NEPC
cohort and the 331R/331 model.
Additional file 2: Table S2. Oncomine analysis revealing significant
overexpression of the 22 selected EpRs. Oncomine analysis revealing
significant overexpression of the 22 selected EpRs in metastatic compared
to non-metastatic prostate cancer across multiple clinical datasets.
Additional file 3: Table S3. Literature-reported direct interactions
between PcG complexes and transcriptional repressors. Literature-
reported direct interactions between PcG complexes and transcriptional
repressors upregulated by at least 1.5-fold in both the clinical NEPC
cohort and the 331R/331 model.
Additional file 4: Table S4. List of investigated PcG genes. Known
members of the PcG family and their associated polycomb repressive
complex.
Additional file 5: Table S5. Patient-derived xenograft models and their
properties. Patient-derived xenograft models from Living Tumor Lab used
for comparative NEPC/PCa analysis and their responses to androgen
stimulation.
Additional file 6: Figure S1. RB1 mRNA levels in patient-derived
xenografts. Expression of CBX2, EZH2, and RB1 in tumor tissue derived
from prostate adenocarcinoma or NEPC.
Additional file 7: Table S6. Gene composition of NEARS. List of 185
overlapping genes significantly downregulated across multiple NEPC
datasets.
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